Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer
A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report at the ESMO 2016 Congress in Copenhagen.
Oct 10, 2016
0
1